SCHEMBL1924901

SCHEMBL1924901

CCOC(=O)c1ccc(Sc2ccc(Cl)cc2)c([N+](=O)[O-])c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 1/20 0.60
GSTM2 P28161 1/20 0.60
BCL2L1 Q07817 2/20 0.58
POLB P06746 2/20 0.58
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
ALDH1A1 P00352 4/20 0.55
LMNA P02545 4/20 0.55
MAPT P10636 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
PLA2G4A P47712 1/20 0.53
PDE7A Q13946 3/20 0.52
PDE7B Q9NP56 2/20 0.52
NPC1 O15118 1/20 0.52
PKM P14618 1/20 0.52
CRHBP P24387 1/20 0.52
RAB9A P51151 1/20 0.52
CRHR2 Q13324 1/20 0.52
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18376682 0.88 GSTP1 (0.60) GSTP1GSTM2POLBKMT2AMEN1
SCHEMBL2960962 0.88 MAPT (0.69) GSTP1GSTM2BCL2L1POLBKMT2A
SCHEMBL1924145 0.87 BCL2L1 (0.64) BCL2L1POLBKMT2AMEN1ALDH1A1
SCHEMBL4004813 0.84 MAPT (0.53) GSTP1GSTM2BCL2L1POLBKMT2A
SCHEMBL4004970 0.84 MAPT (0.52) GSTP1GSTM2BCL2L1POLBKMT2A
SCHEMBL260444 0.82 KMT2A (0.62) GSTP1GSTM2POLBKMT2AMEN1
SCHEMBL13808081 0.82 MAPT (0.51) GSTP1GSTM2BCL2L1POLBKMT2A
SCHEMBL1924148 0.81 BCL2L1 (0.67) BCL2L1POLBKMT2AMEN1ALDH1A1
SCHEMBL1923978 0.81 BCL2L1 (0.74) GSTP1GSTM2BCL2L1POLBKMT2A
SCHEMBL1456061 0.80 GSTP1 (0.52) GSTP1GSTM2POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1757610-B1 CONDENSED PYRIMIDINE DERIVATIVE AND XANTHINE OXIDASE INHIBITOR NIPPON CHEMIPHAR CO (JP) 2011-06-08 EP disclosed
US-7598254-B2 Substituted 1,3-thiazolo[5,4-d]pyrimidines as xanthine oxidase inhibitors NIPPON CHEMIPHAR CO., LTD. (JP) 2009-10-06 US disclosed
US-20070293512-A1 Condensed Pyrimidine Deriviative and Xanthine Oxidase Inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2007-12-20 US disclosed
EP-1757610-A1 CONDENSED PYRIMIDINE DERIVATIVE AND XANTHINE OXIDASE INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293512-A1 Condensed Pyrimidine Deriviative and Xanthine Oxidase Inhibitor XDH, SQOR, PNPO GSTP1 1726/4885GSTM2 2464/4885BCL2L1 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.